- $84.31m
- -$11.33m
- 53
- 46
- 45
- 46
Annual cashflow statement for ImageneBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -44.3 | -34.1 | -68.8 | -68.2 | -49.2 |
| Depreciation | |||||
| Non-Cash Items | 13.9 | 6.35 | 9.04 | 9.07 | 6.72 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.77 | -33 | -15.1 | -21.7 | -3.98 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -37.8 | -60.3 | -74.1 | -79.7 | -46 |
| Capital Expenditures | -0.766 | -1.76 | -1.43 | -0.414 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.69 | — | -97.9 | 64.6 | -34.9 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 2.92 | -1.76 | -99.3 | 64.1 | -34.9 |
| Financing Cash Flow Items | -0.057 | -0.146 | 0 | 39.1 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 116 | 132 | 1.09 | 76 | — |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 81.3 | 69.7 | -172 | 60.4 | -80.9 |